Pathogens and drug resistant rate analysis of aged of bronchiectasis patients in an acute exacerbation

Abstract

Abstract: AIM: To learn the situation of pathogens distribution and drug sensitivity in aged bronchiectasis in an acute exacerbation.METHODS: 150 samples of sputum bacteria culture and drug sensitivity tests from 104 aged patients were performed in our hospital from 2000 to 2012.RESULTS: 107 isolates isolated from 150 sputum samples, among them there were 87 isolates of gram-negative bacillus (81%). The most common Gram-negative bacillus isolated were Pseudomonas aeruginosa(35%), Klebsiella pneumoniae(14% ), Acinetobacter baumannii(11%). There were 8 strains of gram-positive bacteria(7%),12 strains of fungi(11%). Piperacillin/tabazotani, three generation cephalosporin,four generation cephalosporin carbapenem,and quinolone has better antimicrobial activity against. gram-negative bacillus.CONCLUSION: The main pathogen of aged bronchiectasis in an acute exacerbation was gram negative bacteria, pseudomonas aeruginosa was the most commen pathogens among them. Piperacillin/tabazotani, three generation cephalosporin, four generation cephalosporin, carbapenem should be recommended to treat these aged bronchiectasis patients.

Key words: Aged bronchiectasis, Acute exacerbations, Pathogen, Drug sensitivity test

CLC Number:

SONG Xiu-jie, LU Cong-zhe, FANG Ting-zheng, HAN Wen-jie, RUI Meng, OU Min. Pathogens and drug resistant rate analysis of aged of bronchiectasis patients in an acute exacerbation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 914-918.

References

[1] Rademacher J, Welte T.Bronchiectasis-diagnosis and treatment[J]. Dtsch Arztebl Int, 2011, 108(48): 809-815.
[2] Rademacher J, Welte T.Bronchiectasis-diagnosis and treatment[J]. Dtsch Arztebl Int, 2011, 108(48): 809-815.
[3] O'Donnell, A. E. Bronchiectasis[J].. Chest.2008:134;815-823.
[4] Barker AF. Bronchiectasis[J]. NEJM 2002;346(18):1383-93.
[5] Emmons EE. Bronchiectasis from WebMD. 1996-2008. Available online. http://emedicine.medscape.com/article/296961-overview. Accessed July 30th, 2009.
[6] 霍海燕, 萧淑华, 郭苏.104例支气管扩张急性感染的病原学检测及药敏分析[J].黑龙江医学,2007,31(4):286-287.
[7] 张腊梅,朱华.支气管扩张合并感染患者病原学及药敏分析[J].现代医药卫生,2011,27(20):3065-3066.
[8] 王丽娟,106例老年支气管扩张症患者感染加重期病原菌与耐药性分析[J].吉林医学,2011,32(5).
[9] Rosen MJ. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines[J]. Chest,2006;129(1suppl):122S-131S.
[10] Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis[J]. Eur Respir J,2006,28(5):974-979.
[11] Loebinger MR, Wells AU, Hansell DM,et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival[J]. Eur Respir J,2009,34(4): 843-849.
[12] Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis[J]. Chest, 2007, 132(5):1565-1572.
[13] Anwar GA,Bourke SC, Afolabi G,et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis[J]. Respir Med, 2008,102(10):1494-1496.
[14] Figueiredo Bde C, Ibiapina Cda C. The Role of macrolides in noncystic fibrosis bronchiectasis[J]. Pulm Med,2011, Epub 2011 Sep 5.
[15] Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis[J].Chest,2005, 127(4):1420-1426.
[16] Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa[J]. Ann Pharmacother,2005,39(1): 39-44.
[17] Antoniu SA, Trofor AC. Inhaled gentamicin in non-cystic fibrosis bronchiectasis:effects of long-term therapy[J]. Expert Opin Pharmacother, 2011,12(7): 1191-1194.